Case Report: Primary Leptomeningeal Medulloblastoma in a Child: Clinical Case Report and Literature Review

Daria Morgacheva1*, Alexandra Daks1,2*, Anna Smirnova1, Aleksandr Kim1, Daria Ryzhkova1, Lubov Mitrofanova1, Alena Staliarova3, Evgeniya Omelina4, Alexey Pindyurin4, Olga Fedorova1,2, Oleg Shuvalov1,2, Alexey Petukhov1,2 and Yulia Dinikina1*

1 Almazov National Medical Research Centre, Saint Petersburg, Russia, 2 Laboratory of Gene Expression Regulation, Institute of Cytology, Russian Academy of Sciences, Saint Petersburg, Russia, 3 Hematology and Immunology, Oncological Department 3, Belarusian Research Center for Pediatric Oncology, Minsk, Belarus, 4 Laboratory of Cell Division, Department of Regulation of Genetic Processes, Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia

Medulloblastoma is one of the most common pediatric central nervous system malignancies worldwide, and it is characterized by frequent leptomeningeal metastasizing. We report a rare case of primary leptomeningeal medulloblastoma of an 11-year-old Caucasian girl with a long-term disease history, non-specific clinical course, and challenges in the diagnosis verification. To date, 4 cases of pediatric primary leptomeningeal medulloblastoma are reported, and all of them are associated with unfavorable outcomes. The approaches of neuroimaging and diagnosis verification are analyzed in the article to provide opportunities for effective diagnosis of this disease in clinical practice. The reported clinical case of the primary leptomeningeal medulloblastoma is characterized by MR images with non-specific changes in the brain and spinal cord and by 18FDG-PET/CT images with diffuse heterogeneous hyperfixation of the radiopharmaceutical along the whole spinal cord. The immunohistochemistry and next-generation sequencing analyses of tumor samples were performed for comprehensive characterization of the reported clinical case.

Keywords: primary leptomeningeal medulloblastoma, pediatric cancer, next-generation sequencing, central nervous system tumors, oncology

INTRODUCTION

Medulloblastoma (MB) is the most common primary tumor of the central nervous system (CNS) in children and accounts for about 20% of all neoplasms of the CNS and 63% of intracranial embryonal tumors (1–3). In 70% of cases, MB occurs in children under 10 years of age, while the age-specific incidence has two peaks at the age of 1–4 years and 5–9 years with male predominance (3).

Abbreviations: MB, medulloblastoma; CNS, central nervous system; MRI, magnetic resonance imaging; VPS, ventriculoperitoneal shunt.
Primary MB is almost exclusively located in the hemispheres or in the vermis of the cerebellum and is characterized by highly invasive and aggressive growth (2). One of the specific characteristics of MB is a tendency of metastasizing through cerebrospinal fluid (CSF) pathways, and at the time of initial diagnosis, about 35% of patients have a metastatic stage (3). MB is always classified as a grade IV tumor due to its high malignant potential and rapid growth rate (4).

Primary leptomeningeal MB is an extremely rare form and is characterized by diffuse leptomeningeal lesions in the absence of primary masses in the cerebellum. The complexity of diagnosis of primary leptomeningeal form is explained by atypical clinical manifestations and difficulties of differential diagnosis. To the best of our knowledge, this is the fifth reported case of the primary pediatric leptomeningeal form of MB worldwide (Table 1). All of the previously reported cases were also associated with unfavorable outcomes.

To date, it is generally accepted that MB is a heterogeneous group of CNS tumors with different phenotypes, molecular characteristics, responses to anticancer therapy, and clinical outcomes. It is important to mention that for subgrouping MB, both histological and molecular genetic approaches are used to define treatment strategy and prognosis (4–6).

Due to the primary location of MB in the posterior fossa, symptoms and complaints caused by MB are mostly nonspecific and may indicate a wide range of diseases that delay the diagnosis and initiation of the specific treatment. In 20–40% of cases, the predominant clinical symptom of MB is the progression of hypertensive-hydrocephalic syndrome that manifests with headaches, nausea, vomiting, seizures, and depression of consciousness (7, 8). In addition, MB frequently causes the disorders of cerebrospinal fluid (CSF) circulation, which requires immediate treatment, including drainage by surgical implantation of the CSF shunt system (9). Other manifestations, depending on the localization of the primary tumor and metastases, are uncoordinated movements, cranial nerves palsy, nystagmus, diplopia, and restricted eye movements (10, 11).

The typical radiological signs of MB are the presence of a clearly defined mass of the posterior cranial fossa or cerebellum, corresponding to the primary localization, often rounded, with calcifications, cysts and areas of necrosis, and peritumoral edema, frequently with heterogeneous contrast enhancement. Common forms of MB chiefly show isointensity on T2-WI and fluid-attenuated inversion recovery (FLAIR), high intensity on D-WI, and low intensity on apparent diffusion coefficient (ADC) MR images and also demonstrate strong signal intensity on T1-CE after contrast injecting (12). Leptomeningeal foci usually indicate a metastatic form of MB; but in rare cases, it could be the primary lesions. It has been shown that the specific combinations of MRI signs correspond to concrete histological types (13) and even molecular subgroups of MB (14).

Today, the standard treatment of MB is a combination of surgical resection, chemotherapy, and radiation therapy. The therapeutic strategies are various and depend on the risk group of the disease, the age of the patient at the time of diagnosis, as well as the extent of surgical resection and response to chemotherapy. At the same time, there should be noted a tendency toward reducing the intensity of the anticancer treatment in groups with a favorable prognosis and in young children in order to minimize acute and long-term toxicity.

In this article, we report the first case of pediatric primary leptomeningeal medulloblastoma in Russia. The approaches of neuroimaging, histological, and molecular methods of diagnosis were applied to improve the diagnosis of rare cases in clinical practice.

**CASE DESCRIPTION**

An 11-year-old Caucasian girl with severe neurological symptoms was hospitalized at the Department of Pediatric Neurosurgery, Almazov National Medical Research Centre, St Petersburg, in June 2020. By the time of hospitalization, the patient's medical history was 5 months. In March 2020, the patient was admitted to the local hospital with increased fatigue, febrile fever, headaches accompanied by periodic vomiting, diplopia, and decreased visual acuity.

With suspected meningoencephalitis, the patient was admitted for inpatient antibacterial treatment during which the progression of cerebral symptoms up to sopor has been observed. According to the brain and spinal cord MRI with contrast enhancement, no data for the tumor mass were obtained. Occlusive triventricular hydrocephalus, periventricular edema, and diffuse structural changes in the meninges with the signs of inflammation that are typical to leptomeningitis were diagnosed. CSF cytology did not reveal any pathology. To relieve progressive hypertensive-hydrocephalic syndrome, therapy with systemic corticosteroids was initiated, and ventriculoperitoneal shunting was performed. After the surgery was provided, reduction of neurological symptoms and clinical improvement of patient's condition were observed.

At the time of hospitalization at the Almazov National Medical Research Centre, the patient had moderate asthenic syndrome and ataxia. MRI of the brain and spinal cord showed diffuse infiltration of the pia mater and dura mater of the cerebral hemispheres and posterior cranial fossa (PCF) with irregular thickening and contrast enhancement (Figure 1A and Supplementary Figures 1A,B).

Regional edema, cystic transformation, and hemorrhagic impregnation of cerebellar hemispheres, as well as a site of hemosiderin deposition in the cortex of the right frontal lobe, were visualized (Figure 1B and Supplementary Figures 2A,B). Symmetrical expansion of the lateral ventricles and III ventricle, as well as severe periventricular edema, was detected, while the subarachnoid spaces were narrowed (Figure 1C and Supplementary Figure 3).

In the spinal cord, a spindle-shaped lesion with the size of 20 mm × 9 mm × 8 mm (Figure 1D and Supplementary Figure 4) at the level of Th8-Th9 vertebrae was revealed, with hypertense MR signal on T2-WI and STIR and without contrast enhancement (Figure 1E), which has been regarded as myelitis. The contrast enhancement by the pia mater was noted...
throughout the thoracic spinal cord (Figure 1E). Repeated CSF
cytology was normal.

Considering non-specific MRI data, poor accessibility for
biopsy, and high risks of neurological complications, as well
as stable patient’s condition due to the conservative therapy
[acetazolamide 250 mg/day, prednisolone 1 mg/kg/day (35 mg)],
it was decided to continue the diagnostic search.

The whole-body [18F]2-fluoro-2-deoxy-D-glucose positron
emission tomography/computed tomography (18FDG-PET/CT)
allowed to reveal diffuse heterogeneous hyperfixation of the
radiopharmaceutical along the cervical, thoracic, and lumbar
spinal cord segments with a maximum standardized uptake
of 3.12. This PET-CT picture was non-specific and could be
observed in both tumor lesions and inflammatory processes
(Figures 1F,G).

The patient was continuously treated with combined
therapy that included decongestant, desensitizing, antibacterial,
immunomodulation, neurometabolic, and steroid medications,
and her condition remained stable for 1 month.

However, upon the attempt to reduce the doses of steroid
therapy, there was a deterioration of neurological symptoms
with a progressive disturbance of consciousness level, increased
ataxia, stiffness of the occipital muscles, paraesthesia of the lower
extremities to 2 points, accession of ptosis of the right eyelid, and
decline in visual acuity.

The subsequent MRI examinations revealed an increased size
of nodular thickenings of dura mater in the area of the tentorium
cerebelli (Figure 2A and Supplementary Figures 5A,B); increased
cerebral edema in the area of frontal lobes, in the
poles of the temporal lobes and cerebellar hemispheres; persisted
and progressed diffuse infiltrative changes in the meninges; and
increased zones of cystic transformation of the medulla in the
cerebellum and frontal lobes (Figures 2B,C and Supplementary
Figure 6). Due to the impairment of the patient’s status and
negative dynamics of neuroimaging data, a biopsy of the
pathological region of the cerebellar pia mater was performed
(6 months after the clinical manifestation of the disease).

As a result of the histomorphological examination, among
the fibrous tissue, the complexes of small atypical cells with
a narrow rim of the cytoplasm and hyperchromic nuclei were
identified (Figure 3A). Tumor cells showed positive staining
with antibodies against synaptophysin, MyoD1, filamin A, β-
catenin, INI1, and GAB1 (Figure 3). Ki-67 staining revealed
70% positive cells. Based on the obtained histomorphological and
immunohistochemical data, leptomeningeal medulloblastoma
Grade IV, WNT molecular subgroup was diagnosed. Adjuvant
therapy was not carried out due to the progressive impairment
of the patient’s condition, and the patient died 42 days
after the biopsy.

**DISCUSSION**

The primary leptomeningeal form of MB is an extremely rare
malignancy and is associated with tumor aggressiveness and
an unfavorable prognosis. The non-specific clinical picture,
combined with the difficulties of diagnosis verification, led to a
long diagnostic period, which also causes significant deterioration
of the prognosis. In the analyzed clinical case, there was a 6-
month interval from the manifestation of the disease to the
hospitalization in a specialized oncology department where the
diagnosis has been verified.

According to the literature, this is the fifth reported clinical
case of the primary leptomeningeal form of MB in a child
(Table 1). At the moment of clinical manifestation of the
disease, almost all patients had cerebral symptoms (15–18). The
median age at diagnosis was 9 years (range 5–11 years) with
male predominance (15–18). MRI scans showed predominantly

**TABLE 1 | Reported cases of pediatric primary leptomeningeal MB.**

| Year of report | Age, sex | Symptoms | Initial radiological picture | Surgical intervention, chemotherapy | Histological and molecular subgroup | Outcome | References |
|---------------|----------|----------|-----------------------------|-------------------------------------|-----------------------------------|---------|------------|
| 1989          | 5, M     | Headache, vomiting, decreased consciousness | Widespread diffusion in the subarachnoid spaces of the posterior fossa | Cranietomy | MB | Fatal | (15) |
| 2007          | 10, F    | Increasing headaches, vomiting, altered sensorium | Lesions of all posterior fossa leptomeninges | Lateral suboccipital cranietomy and biopsy; adjuvant chemotherapy | MB | Expired after 2 weeks after surgery | (16) |
| 2009          | 8, M     | Headache, progressive amblyopia during 2 months | Lesion of the meninges in the projection of the cerebellar folia and convexity surfaces of the brain without intraparenchyma y lesions | Suboccipital craniotomy, biopsy; 2 chemotherapy cycles (the Head Start III protocol) | MB | Death 8 months after the onset of the disease | (17) |
| 2018          | 11, M    | Occipital dominant headaches for a year. Generalized tonic spasm and upward tonic deviation of eyes. An episode of projectile vomiting. | Massive hydrocephalus. Nodular pachymeningeal enhancement in cerebellar hemisphere | Emergency surgical decompression, suboccipital cranietomy, biopsy. Radiation and chemotherapy | MB, classic non-WNT/non-SHH | The patient was stable and received the therapy at the time of publication | (18) |

The table includes all reported cases of pediatric primary leptomeningeal form of MB. M, male; F, female; MB, medulloblastoma.
Morgacheva et al. Primary Leptomeningeal Medulloblastoma in a Child

FIGURE 1 | CNS MRI and the whole-body PET-CT of the patient carried out at the time of admission to the Almazov National Medical Research Centre. (A) Brain MRI (CE T1-WI). Diffuse infiltration of the meninges (soft and hard) of the cerebral hemispheres with uneven thickening and contrast accumulation. (B) Brain MRI (T2*-WI). The area of hemosiderin deposition in the cortex of the right frontal lobe. (C) Brain MRI (T2-WI). Triventricular hydrocephalus. Ventricleperitoneal shunting (VPS), the shunt in the left lateral ventricle. Severe periventricular edema. Subarachnoid spaces are narrowed. (D) Spinal cord MRI (STIR). The spinal cord at the level of Th8-Th9 vertebrae is thickened, and a spindle-shaped formation of 22 mm x 9 mm x 8 mm is observed. (E) Spinal cord MRI (post-contrast T1-WI). The pia mater of the thoracic region of spinal cord evenly accumulates a contrast agent. The spindle-shaped formation shows no signs of contrast. (F,G) The whole-body [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET-CT). The picture of diffuse heterogeneous hyperfixation of the radiopharmaceutical along the course of the cervical, thoracic, and lumbar segments of the spinal cord with a maximum value of standardized drug capture of 3.12.

We report this case to pay attention to the features of the manifestation and hence to increase the chances of its timely diagnosis in the future. The complexity of clinical and laboratory data makes it possible to suspect the oncological diagnosis. Attention should be paid to the presence of cerebral symptoms at the onset of the disease (headaches accompanied by periodic vomiting, double vision, and deterioration of visual acuity). At the same time, according to the MRI data, tumor mass was not detected; however, the infiltration and thickening of the meninges of the brain were noted, as well as the signs of occlusive triventricular hydrocephalus and periventricular cerebral edema. Importantly, some advanced MRI protocols, such as diffusion tensor imaging (DTI), and simple quantified basic MRI sequence analysis are successfully used for the differentiation of medulloblastomas, glial tumors, and ependymomas (19, 20).

Furthermore, in the absence of pathological changes according to the examination of CSF, as well as the exclusion of bacterial, tuberculous, viral and fungal brain lesions, and autoimmune encephalitis (confirmed by the presence of antibodies in meningial lesions with contrast enhancement but there were no definite lesions in the brain parenchyma (15–18). All patients underwent a biopsy with a subsequent histological examination that verified the diagnosis of MB (15–18). Given the years of published cases, the identification of the molecular subgroup of MB was performed only in one case, and the subgroup non-WNT/non-SHH was defined (18). All patients died a few weeks after the manifestation of the disease.
peripheral blood and cerebrospinal fluid to NMDA receptors), the patient must be referred to a specialized oncological hospital to exclude cancer. Early biopsy with subsequent histological examination should be performed to verify the diagnosis and select the treatment options.

It is necessary to underline that in our case, the lack of tumor samples was a limiting factor for using standard diagnostic technologies. Our objective was to provide an integrated diagnosis with molecular analysis considering the rarity of the form of MB.

Another important problem that should be addressed is the lack of sufficient publicly available databases containing genomic sequencing data of patients with MB, in particular with the primary leptomeningeal form of MB. A biopsy sample from the patient was used for targeted next-generation sequencing (NGS) of the previously described cancer-related
genes (21). The subsequent NGS data analysis was performed using previously described tools (22–28), which revealed in total 1,808 nucleotide sequence variations (Supplementary Table 1). Nine of the identified single-nucleotide variants (SNVs), within the coding sequences of the BRCA2, CHEK2, ERBB2, FLT3, IDH1, KDR, MC1R, RNF43, and SLC45A2 genes, were considered to be potentially significant (29). To classify the molecular subgroup of MB, the nucleotide sequence variations found in the patient's biopsy sample were compared with those identified in a whole-genome study of 491 MB samples (30). Since such comparisons did not identify a single overlapping mutation, the affected genes were then compared. In total, 36 genes were common between the case tumor sample and the drivers identified in the whole-genome study (Supplementary Table 2). However, the comparison of the patterns of gene mutations in the molecular subgroups of MB (30) with that in the case tumor sample resulted in very low Pearson’s correlation coefficients (0.099, −0.157, 0.047, and −0.070) between the studied sample and the WNT, SHH, Group 3, and Group 4 subgroups of MB, respectively (Supplementary Table 2). Thus, the classification of the molecular subgroup for the studied sample of MB appeared to be impossible. We consider that to determine the subgroup of MB, it is necessary to expand the number of studied genes and study as many clinical samples as possible. Subsequently, this can facilitate both accurate subtyping of the tumor and the timely selection of the optimal therapy.

CONCLUSION

Diagnosis of primary leptomeningeal MB is challenging due to non-specific clinical symptoms, atypical radiological picture, and rapidly progressive nature of the disease that requires early biopsy with a subsequent histological examination to verify pathological process and initiate therapy. Primary leptomeningeal MB harbor unfavorable outcome that is explained by diagnostic difficulties, rapid clinical deterioration, and unsatisfactory therapy response. Also, it cannot be ruled out that unfavorable outcome is explained by specific somatic mutations in tumor or hereditary cancer predisposition syndrome.

DATA AVAILABILITY STATEMENT

The dataset presented in this study can be found in Mendeley Data repository (doi: 10.17632/98nt6b9dvc.1).

AUTHOR CONTRIBUTIONS

YD and AK performed the diagnostics and treatment of the patient. YD, DM, AD, AS, and AP contributed to the conceptualization of the study. DM, YD, ASm, AD, DR, LM, AS, OF, OS, and AP wrote and edited the manuscript. EO and API performed the bioinformatic analysis of the NGS data. All authors participated in group discussions and in commenting upon drafts of the manuscript.

FUNDING

This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022-301).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.925340/full#supplementary-material

Supplementary Figure 1 | Contrast-enhancing CNS MRI (CE T1-WI). MRI showing diffuse meningeal enhancement (green arrows) in cerebral hemispheres (A) and posterior cranial fossa (B).

Supplementary Figure 2 | CNS MRI (A). T2-WI (B). TIRM zones of edema, hemorrhagic impregnation, cortical cystic lesions.

Supplementary Figure 3 | CNS MRI TIRM. VPS shunt in the left lateral ventricle, periventricular edema; subarachnoid space is narrowed.

Supplementary Figure 4 | Spinal cord MRI (T2-WI).

Supplementary Figure 5 | CNS MRI of the patient after 5.5 months of the debut of the disease. (A) Brain MRI (post-contrast CE T1-WI). (B) Brain MRI (post-contrast CE T1-iso-WI). Accumulation of contrast agent by thickened meninges in cerebellar tentorium.

Supplementary Figure 6 | CNS MRI of the patient after 5.5 months of the debut of the disease. Brain MRI (T2-WI).

Supplementary Table 1 | Nucleotide variations identified in the tumor sample by targeted NGS. Raw NGS data were generated using NextSeq 500 System (Illima, United States) and subjected to the standard analysis, which included FASTQ data generation, quality filtering, and mapping to the human HG19 (GRCh37.p13) genome assembly using bowtie2 (22) (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml), that resulted in the generation of BAM file for the tumor sample. MuTect2 algorithm from the GATK toolset (23) (https://gatk.broadinstitute.org/hc/en-us/articles/360037593851-MuTect2) was used. "tumor only" mode was used to identify mutations in the BAM file, resulting in the generation of the unfiltered output VCF file. Filtration of raw output of MuTect2 was made using the FilterMutectCalls tool from the GATK toolset (23) (https://gatk.broadinstitute.org/hc/en-us/articles/360036856831-FilterMutectCalls) with --min-allele-fraction 0.4. To remove all mutations that did not pass the filter and with read depth less than 15 (--min-meanDP 14), we used VCFTools (24) (https://vcftools.github.io/index.html). Annotation of identified mutations was done with the SnpEff tool (25) (http://snpeff.sourceforge.net/SnpEff/). The potential pathogenic significance of nucleotide variations was evaluated using the CADD algorithm (SIFTcat) (28).

Supplementary Table 2 | Attempt to classify the molecular subgroup of the case tumor sample based on the identified nucleotide variations. To properly compare the patterns of gene mutations in the case tumor sample and in the driver genes defined for molecular subgroups of MB earlier (30), we first processed single-nucleotide variants (SNVs) and insertions/deletions (InDels) identified (30) exactly in the same way as it was done for nucleotide variations found in the case tumor sample. Next, genes with at least one mutation with CADD PHRED-like
value (PHRED) < 15 were arbitrarily assigned a score of 0.5; genes with at least one mutation with PHRED ≥ 15 and classified by PolyPhenCat as “probably damaging” or “possibly damaging” were arbitrarily assigned a score of 2.0; other genes with at least one mutation with PHRED ≥ 15 were arbitrarily assigned a score of 1.0. Then, using the information on the frequency of mutations in each gene in molecular subgroups of MB, we computed the weighted score of each driver gene in each molecular subgroup, by multiplying the arbitrarily assigned scores by mutation frequencies. A comparison of gene scores obtained for the studied tumor sample with the weighted scores computed for the driver genes was performed by calculating the Pearson’s correlation coefficients.

REFERENCES

1. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neuroectodermal tumours in adults and children. J Clin Neurosci. (2012) 19:1541–4. doi: 10.1016/j.jocn.2012.04.009

2. Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev Dis Primers. (2019) 5:11. doi: 10.1038/s41572-019-0063-6

3. Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review: JNSPG 75th Anniversary invited review article. J Neurosurg Pediatr. (2019) 24:353–63. doi: 10.3171/2019.5.PEDS18581

4. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. (2021) 23:1231–51. doi: 10.1093/neuros/ncab106

5. Orr BA. Pathology, diagnostics, and classification of medulloblastoma. Brain Pathol. (2020) 30:664–78. doi: 10.1111/bpa.12837

6. Taylor MD, Northcott PA, Korshunov A, Cho Y-J, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. (2012) 123:465–72. doi: 10.1007/s00401-011-0922-2

7. Halperin EC, Watson DM, George SL. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. J Pediatr. (2001) 91:1444–50. doi: 10.1002/1097-0125(20010415)91:8<1444::AID-CNCR1151>3.0.CO;2-U

8. Brasse J-F, Chalumeau M, Doz F, Jacquot B, Viallet-Couanet D, Gaillard S, et al. Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study. Eur J Pediatr. (2012) 171:25–32. doi: 10.1007/s00431-011-1480-z

9. Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U, et al. Clinical implications of medulloblastoma subgroups: incidence of CSF dissemination surgery. J Neurosurg Pediatr. (2015) 15:236–42. doi: 10.3171/2014.9.PEDS14280

10. Cassidy L, Stirling R, May K, Picton S, Doran R. Ophthalmic complications of childhood medulloblastoma. Med Pediatr Oncol. (2000) 34:43–7. doi: 10.1002/(SICI)1096-911X(20000131)34:1<43::AID-MPO8-3.0.CO;2-H

11. Quinan A, Rizzolo D. Understanding medulloblastoma. J Am Acad Phys Assist. (2017) 30:30–60. doi: 10.1097/01.JAAP.0000524717.71084.50

12. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277

13. Sokolenko AP, Gorodnova TV, Bizin IV, Kulagina ES, Kotiv KB, Romanko AA, et al. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients. Cancer Chemother Pharmacol. (2021) 88:439–50. doi: 10.1007/s00280-021-04301-6

14. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277

15. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277

16. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277

17. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277

18. Duc NM, Huy HQ, Nadarajan C, Keserci B. The role of predictive model based on quantitative basic magnetic resonance imaging in differentiating medulloblastoma from ependymoma. Anticancer Res. (2020) 40:2975–80. doi: 10.21873/anticancer.14277